Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Extended use of P504S Positive Primary Circulating Prostate Cell Detection to Determine the Need for Initial Prostate Biopsy in a Prostate Cancer Screening Program in Chile

  • Published : 2014.11.28
Download PDF
⟨ Previous Next ⟩

Abstract

Background: To determine the frequency of primary circulating prostate cells (CPC) detection according to age and serum PSA levels in a cohort of men undergoing screening for prostate cancer and to determine the diagnostic yield in those men complying with the criteria for prostate biopsy. Materials and Methods: A prospective study was carried out to analyze all men evaluated in a hospital prostate cancer screening program. Primary CPCs were obtained by differential gel centrifugation and detected using standard immunocytochemistry using anti-PSA, positive samples undergoing a second process with anti-P504S. A malignant primary CPC was defined as PSA+ P504S+, and a test positive if 1 cell/4ml was detected. The frequency of primary CPC detection was compared with age and serum PSA levels. Men with a PSA >4.0ng/ml and/or abnormal rectal examination underwent 12 core prostate biopsy, and the results were registered as cancer/no-cancer and compared with the presence/absence of primary CPCs to calculate the diagnostic yield. Results: A total of 1,117 men participated; there was an association of primary CPC detection with increasing age and increasing serum PSA. Some 559 men underwent initial prostate biopsy of whom 207/559 (37.0%) were positive for primary CPCs and 183/559 (32.0%) had prostate cancer detected. The diagnostic yield of primary CPCs had a sensitivity of 88.5%, a specificity of 88.0%, and positive and negative predictive values of 78.3% and 94.9%, respectively. Conclusions: The use of primary CPCs for testing is recommended, since its high negative predictive value could be used to avoid prostate biopsy in men with an elevated PSA and/or abnormal DRE. Men positive for primary CPCs should undergo prostate biopsy. It is a test that could be implemented in the routine immunocytochemical laboratory.

Keywords

References

  1. Aus G (1994) Prostate cancer: mortality and morbidity after non-curative treatment with aspects on diagnosis and treatment. Scand J Urol Nephrol Suppl, 167, 1-41.
  2. Beach R, Gown AM, Peralta-Venturina MN et al (2002). P504S immunohistochemical detection in 405 prostatic specimens including 376 18-guage needle biopsies. Am J Surg Pathol 26, 1588-96. https://doi.org/10.1097/00000478-200212000-00006
  3. Borgen E, Naume B, Nesland JM, et al (1999) Standardization of the immunocitochemical detection of cancer cells in bone marrow and blood: Establishment of objective criteria for the evaluation of immunostained cells. ISHAGE Cytotherapy, 5, 377-88.
  4. Bozeman CB, Carver BS, Eastman JA et al (2002). Treatment of chronic prostatitis lowers serum PSA. J Urol, 167, 1723-26. https://doi.org/10.1016/S0022-5347(05)65186-5
  5. Davis JW, Nakanishi H, Kumar VS, et al (2008). Circulating tumor ce-lls in peripheral blood samples from patients with increased serum prostate specific antigen: initial results in early prostate cancer. J Urol, 179, 2187-91. https://doi.org/10.1016/j.juro.2008.01.102
  6. De Visschere P, Oosterlink W, De Meerleer G et al (2010). Clinical and imaging tools in the early diagnosis of prostate cancer: a review. JBR-BTR, 93, 62-70.
  7. Draisma G, Boer R, Otto SJ et al (2003). Active treatment for PSA screening detected prostate cancer. J Natl Cancer Inst. 95, 868-78. https://doi.org/10.1093/jnci/95.12.868
  8. Epstein JI, Walsh PC, Carmichael M et al (1994). Pathological and clinical findings to predict tumor extent of non-palpable (stage T1c) prostate cancer. JAMA, 271, 368-74. https://doi.org/10.1001/jama.1994.03510290050036
  9. Eschwege P, Moutereau S, Droupy S, et al (2009). Prognostic value of prostate circulating cells detection in prostate cancer patients: a prospective study. Br J Cancer. 100, 608-10. https://doi.org/10.1038/sj.bjc.6604912
  10. Fehm T, Sotomayer EF, Meng S, et al (2005). Methods for isolating epi-thelial cells and criteria for their classification as carcinoma cells. Cytotherapy, 7, 171-85. https://doi.org/10.1080/14653240510027082
  11. Fizazi K, Morat L, Chauveinc L, et al (2007). High detection rate of circulating tumor cells in blood of patients with prostate cancer using telomerase activity. Ann Oncol, 18, 518-21.
  12. Fu-Bin Wang (2011). A higher number of CTCs in peripheral blood indicates poor prognosis in prostate cancer patients:A meta-analysis. Asian Pac J Cancer Prev, 12, 2629-35.
  13. Helo P, Cronin AM, Danila DC, et al (2009). Circulating pros-tate tumor cells detected by RT-PCR in men with localized or castrate refractory prostate cancer: concordance with CellSearch assay and association with bone metastasis and with survival. Clin Chem, 55, 765-73. https://doi.org/10.1373/clinchem.2008.117952
  14. Mikolajczyk SD, Millar LS, Tsinberg P, et al (2011). Detection of EpCAM negative and cytokeratin negative circulating tumor cells in peripheral blood. J Oncol, 10, 1155.
  15. Moll R, Divo M, Langbein L (2008). The human keratins: biology and pathology. Histochem Cell Biol, 129, 705-33. https://doi.org/10.1007/s00418-008-0435-6
  16. Moreno JG, Croce CM, Fischer R,et al (1992). Detection of hematogenous micrometastasis in patients with prostate cancer. Cancer Res, 52, 6110-2.
  17. Murray NP, Calaf GM, Badinez L et al (2010). P504S expressing circulating prostate cells as a marker for prostate cancer. Oncol Reports, 24, 687-692.
  18. Murray NP, Reyes E, Badinez et al (2013). Circulating prostate cells found in men with benign prostate disease are P504S negative. J Oncol, 10, 1155.
  19. Murray NP, Reyes E, Orellana N et al (2013a). Secondary circulating prostate cells predict biochemical failure in prostate cancer patients after radical prostatectomy and without evidence of disease. Sci World J, 10, 1155.
  20. Murray NP, Reyes E, Orellana N et al (2014). A comparative performance analysis of total PSA, percentage free PSA, PSA velocity, and PSA density versus the detection of primary circulating prostate cells in predicting initial prostate biopsy findings in Chilean men. BioMed Research Int, 10, 1155.
  21. Osman I, Scher HI, Drobnjak M, et al (2001). HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer. Clin Cancer Res, 7, 2643-7.
  22. Panteleakou Z, Lembessis P. Sourla A, et al (2009). Detection of circulating tumor cells in prostate cancer patients: methodological pitfalls and clinical relevance. Mol Med 15, 101-14.
  23. Par Kah D, Lal M, Hashmi AH et al (2014). Utility of DRE, serum PSA and TRUS in the detection of prostate cancer: A developing Country Perspective. Asian Pac J Cancer Prev, 15, 3087-91. https://doi.org/10.7314/APJCP.2014.15.7.3087
  24. Paterlini-Brechot P, Benali NL (2007). Circulating tumor cells detection: clinical impact and future directions. Cancer Letters, 2, 180-204.
  25. Postma R, Schroeder FH (2005). Screening for prostate cancer. Eur J Cancer, 41, 825-33. https://doi.org/10.1016/j.ejca.2004.12.029
  26. Pungalia RS, D'Amico AV, Catalona WJ et al (2006). Impact of age, benign prostatic hyperplasia and cancer on PSA level. Cancer, 106, 1507-113. https://doi.org/10.1002/cncr.21766
  27. Raimondi C, Gradilone A, Naso G, et al (2011). Epithelialmesenchymal transition and stemness features in circulating tumor cells from breast cancer patients. Breast Cancer Res Treat, 130, 449-55. https://doi.org/10.1007/s10549-011-1373-x
  28. Rietbergen JB, Kruger AE, Krause R, Schroder F (1997). Complications of transrectal ultrasound guided systematic sextant biopsies of prostate: evaluation of complication rates and risk factors within a population based screening population. Urol, 49, 875-880. https://doi.org/10.1016/S0090-4295(97)00100-3
  29. Rubin MA, Zhou M, Dhanasekaran SM (2002). Alpha-methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA, 287, 1662-70. https://doi.org/10.1001/jama.287.13.1662
  30. Schaffer DR, Leversha MA, Danila DC (2007). Circulating tumor cell analysis in patients with progressive castration resistant prostate cancer. Clin Cancer Res, 13, 2023-9. https://doi.org/10.1158/1078-0432.CCR-06-2701
  31. Schroder FHJ, van der Cruijsen-Koeter HJ, de Koning AN et al (2000). Prostate cancer detection at low PSA. J Urol, 163, 806-12. https://doi.org/10.1016/S0022-5347(05)67809-3
  32. Stott SL, Lee RJ, Nagrath S, Yu M, et al (2010). Isolation and characterization of circulating tumor cell from patients with localized and metastatic prostate cancer. Sci Transl Med, 25, 25
  33. Thompson IM, Goodman PJ, Tangen CM et al (2003). The influence of finisteride on the development of prostate cancer. N Eng J Med, 349, 215-24. https://doi.org/10.1056/NEJMoa030660
  34. Went PT, Lugli A, Meier S et al (2004). Frequent EpCam protein expression in human carcinomas. Hum Pathol, 1, 122-8.
  35. Zheng XY, Zhang P, Xie LP et al (2014). PSAV and PSAV per intial volume for early detection of prostate cancer. Asian Pac J Cancer Prev, 13, 5529-33.
  36. Zhou M, Chinnaiyan AM, Lleer CG et al (2002). Alpha-methylacyl-CoA racemase: a novel tumor. Surg Pathol, 26, 926-31. https://doi.org/10.1097/00000478-200207000-00012

Cited by

  1. Comparison of the Formula of PSA, Age, Prostate Volume and Race Versus PSA Density and the Detection of Primary Malignant Circulating Prostate Cells in Predicting a Positive Initial Prostate Biopsy in Chilean Men with Suspicion of Prostate Cancer vol.16, pp.13, 2015, https://doi.org/10.7314/APJCP.2015.16.13.5365
  2. Human Kallikrein-2, Prostate Specific Antigen and Free-Prostate Specific Antigen in Combination to Discriminate Prostate Cancer from Benign Diseases in Syrian Patients vol.16, pp.16, 2015, https://doi.org/10.7314/APJCP.2015.16.16.7085
  3. Prostate Cancer Screening in the Fit Chilean Elderly: a Head to Head Comparison of Total Serum PSA versus Age Adjusted PSA versus Primary Circulating Prostate Cells to Detect Prostate Cancer at Initial Biopsy vol.16, pp.2, 2015, https://doi.org/10.7314/APJCP.2015.16.2.601